T Cell Lymphoma clinical trials at UC Irvine

• A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

  open to eligible people ages 18 years and up

  This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL).

  Irvine, California and other locations

• A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

  Sorry, not currently recruiting here

  The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR). A lead-in dose-finding part was used to determine dose level 9 microgram per kilogram (mcg/kg) E7777 that is being used to test efficacy and safety.

  Orange, California and other locations

Last updated: October 8, 2020